In contrast to breast, rectal, and esophageal cancers, complete pathologic responses to neoadjuvant chemotherapy occur in only 5–7.5% of cases.Cancer patients have benefited from the development and expansion of personalized medicine and immunotherapy, particularly with the use of immune checkpoint inhibitors (ICI). Drugs targeting CTLA-4, PD-1, and PD-L1 have been far more effective in the management of melanoma and lung cancer than cytotoxic chemotherapy alone. Read more . . .
Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat; the 5 year-survival rate across all stages is 7.9% in the United States. Approximately 20% of patients are candidates for surgical intervention at the time of diagnosis. As a result, there has been increasing interest in expanding the armamentarium of neoadjuvant therapies aimed at decreasing tumor burden and selecting patients with favorable tumor biology prior to curative-intent surgery, particularly for locally advanced and borderline resectable PDAC.